Phase 2 Readout~quarter

Phase 2 Readout: kt-621

Drug
kt-621
Indication
moderate to severe AD

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Readout: kt-621 — KYMR Phase 2 Readout | BioSniper